GlassScriptPhysician profile
Maggie Doty Lewis
NPI 1427438001
$7,361.50
in general payments reported to CMS, 2019-2025
44 companies · $2,365 in 2025
The $2,365 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.94 · 2022: $664 · 2023: $2,044 · 2024: $2,251 · 2025: $2,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,651 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,650.83 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,219.81 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $918.07 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $798.10 | 2022-2025 | |
| Amgen INC. | $687.10 | 2021-2025 | Evenity, Prolia, Repatha |
| Corcept Therapeutics | $584.50 | 2023-2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $371.77 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $265.13 | 2022-2025 | |
| Dexcom, INC. | $232.66 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $188.07 | 2023-2025 | |
| Averitas Pharma INC. | $177.00 | 2023-2025 | Qutenza |
| Astellas Pharma US INC | $151.86 | 2022-2025 | Veozah, Myrbetriq |
| Xeris Pharmaceuticals, INC. | $149.09 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Glaxosmithkline, LLC. | $148.37 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $133.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Tandem Diabetes Care, INC. | $128.22 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.57 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $109.57 | 2022-2025 | Farxiga, Bevespi Aerosphere |
| Takeda Pharmaceuticals U.S.A., INC. | $101.00 | 2022-2025 | Trintellix |
| Medtronic, INC. | $86.91 | 2024 | Minimed 780g |
| Abbott Laboratories | $79.44 | 2022-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $66.35 | 2022-2023 | Belsomra |
| Almatica Pharma LLC | $49.89 | 2023-2025 | Loreev Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $47.08 | 2022 | |
| Daiichi Sankyo INC. | $44.11 | 2025 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $43.98 | 2024-2025 | Iqirvo, Bylvay |
| Otsuka America Pharmaceutical, INC. | $39.69 | 2024-2025 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $38.86 | 2025 | Libtayo |
| Ibsa Pharma INC. | $35.93 | 2023-2025 | Tirosint, Licart, Flector |
| Axsome Therapeutics, INC. | $32.87 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $32.20 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $31.70 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.51 | 2025 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $26.80 | 2023 | |
| Beta Bionics, INC. | $24.91 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Janssen Biotech, INC. | $24.33 | 2024 | Stelara |
| Sanofi-Aventis U.S. LLC | $21.43 | 2023 | |
| Neurocrine Biosciences, INC. | $20.88 | 2025 | |
| Insulet Corporation | $16.00 | 2022 | |
| Esperion Therapeutics, INC. | $15.66 | 2025 | Nexletol |
| Halozyme INC | $14.12 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.63 | 2025 | Zoryve |
| Antares Pharma, INC. | $13.32 | 2024 | Xyosted |
| Corium, LLC | $13.16 | 2023 | Azstarys |
| Cequr Corporation | $11.00 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maggie Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.